PDF herunterladen
Clin Colon Rectal Surg 2013; 26(02): 067-074
DOI: 10.1055/s-0033-1348043
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Medical Management of Crohn Disease

Frank I. Scott
1   Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
,
Mark T. Osterman
1   Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. Juni 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Crohn disease (CD) is one of the major subtypes of inflammatory bowel disease and can occur in any segment of the alimentary tract. There have been significant advances in the medical therapy of CD over the past several decades. For mild CD, the oral corticosteroid derivative budesonide has demonstrated superior efficacy compared with traditional therapies such as 5-aminosalicylic acid, and can be used concurrently with these agents. For the management of moderate to severe disease, the immunomodulators azathioprine, 6-mercaptopurine, and methotrexate, as well as the antitumor necrosis factor-alpha (TNF-α) agents infliximab, adalimumab, and certolizumab pegol, have become the mainstay of therapy, with growing interest in combining these agents for maximal effect. Immunomodulators and anti-TNF-α agents have also demonstrated benefit in fistulizing CD. There has been growing evidence suggesting that both of these agents, along with the antibiotics metronidazole and ornidazole, are also effective in preventing postoperative recurrence of CD.

Keywords

Crohn disease - antitumor necrosis factor-alpha - immunomodulators - 5-aminosalicylic acid - budesonide
 

  • References

  • 1 Caprilli R, Cesarini M, Angelucci E, Frieri G. The long journey of salicylates in ulcerative colitis: The past and the future. J Crohn's Colitis 2009; 3 (3) 149-156
    PubMedSuche in Google Scholar
  • 2 Peppercorn MA, Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973; 64 (2) 240-245
    PubMedSuche in Google Scholar
  • 3 Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95 (12) 3452-3457
    PubMedSuche in Google Scholar
  • 4 Haskó G, Szabó C, Németh ZH, Deitch EA. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 2001; 103 (4) 473-478
    CrossrefPubMedSuche in Google Scholar
  • 5 Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999; 116 (3) 602-609
    CrossrefPubMedSuche in Google Scholar
  • 6 Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2010; (12) CD008870
    PubMedSuche in Google Scholar
  • 7 Edsbäcker S, Andersson P, Lindberg C, Paulson J, Ryrfeldt A, Thalén A. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos 1987; 15 (3) 403-411
    PubMedSuche in Google Scholar
  • 8 Greenberg GR, Feagan BG, Martin F , et al; Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331 (13) 836-841
    CrossrefPubMedSuche in Google Scholar
  • 9 Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. The Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997; 41 (2) 209-214
    CrossrefPubMedSuche in Google Scholar
  • 10 Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; (3) CD000296
    PubMedSuche in Google Scholar
  • 11 Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35 (3) 360-362
    CrossrefPubMedSuche in Google Scholar
  • 12 Modigliani R, Mary JY, Simon JF , et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98 (4) 811-818
    CrossrefPubMedSuche in Google Scholar
  • 13 Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest 2003; 111 (8) 1122-1124
    CrossrefPubMedSuche in Google Scholar
  • 14 Tiede I, Fritz G, Strand S , et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111 (8) 1133-1145
    CrossrefPubMedSuche in Google Scholar
  • 15 Dubinsky MC, Lamothe S, Yang HY , et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118 (4) 705-713
    CrossrefPubMedSuche in Google Scholar
  • 16 Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32 (5) 651-662
    PubMedSuche in Google Scholar
  • 17 Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; (6) CD000545
    PubMedSuche in Google Scholar
  • 18 Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; (1) CD000067
    PubMedSuche in Google Scholar
  • 19 Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130 (4) 1047-1053
    CrossrefPubMedSuche in Google Scholar
  • 20 Haines ML, Ajlouni Y, Irving PM , et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17 (6) 1301-1307
    CrossrefPubMedSuche in Google Scholar
  • 21 Beaugerie L, Brousse N, Bouvier AM , et al; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374 (9701) 1617-1625
    CrossrefPubMedSuche in Google Scholar
  • 22 Peyrin-Biroulet L, Khosrotehrani K, Carrat F , et al; Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141 (5) 1621-1628 , e1–e5
    CrossrefPubMedSuche in Google Scholar
  • 23 Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143 (2) 390-399 , e1
    CrossrefPubMedSuche in Google Scholar
  • 24 Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141 (5) 1612-1620
    CrossrefPubMedSuche in Google Scholar
  • 25 Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8 (3) 268-274
    CrossrefPubMedSuche in Google Scholar
  • 26 Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001; 60 (8) 729-735
    CrossrefPubMedSuche in Google Scholar
  • 27 Feagan BG, Rochon J, Fedorak RN , et al; The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332 (5) 292-297
    CrossrefPubMedSuche in Google Scholar
  • 28 Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005; (1) CD003459
    PubMedSuche in Google Scholar
  • 29 Feagan BG, Fedorak RN, Irvine EJ , et al; North American Crohn's Study Group Investigators. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000; 342 (22) 1627-1632
    CrossrefPubMedSuche in Google Scholar
  • 30 Khan N, Abbas AM, Whang N, Balart LA, Bazzano LA, Kelly TN. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18 (2) 359-367
    CrossrefPubMedSuche in Google Scholar
  • 31 Van den Brande JM, Braat H, van den Brink GR , et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124 (7) 1774-1785
    CrossrefPubMedSuche in Google Scholar
  • 32 ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50 (2) 206-211
    CrossrefPubMedSuche in Google Scholar
  • 33 Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121 (5) 1145-1157
    CrossrefPubMedSuche in Google Scholar
  • 34 Knight DM, Trinh H, Le J , et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30 (16) 1443-1453
    CrossrefPubMedSuche in Google Scholar
  • 35 Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 1999; 58 (Suppl. 01) I70-I72
    CrossrefPubMedSuche in Google Scholar
  • 36 Sandborn WJ, Feagan BG, Stoinov S , et al; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357 (3) 228-238
    CrossrefPubMedSuche in Google Scholar
  • 37 Targan SR, Hanauer SB, van Deventer SJ , et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337 (15) 1029-1035
    CrossrefPubMedSuche in Google Scholar
  • 38 Hanauer SB, Feagan BG, Lichtenstein GR , et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317) 1541-1549
    CrossrefPubMedSuche in Google Scholar
  • 39 Hanauer SB, Sandborn WJ, Rutgeerts P , et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2) 323-333 , quiz 591
    CrossrefPubMedSuche in Google Scholar
  • 40 Sandborn WJ, Hanauer SB, Rutgeerts P , et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56 (9) 1232-1239
    CrossrefPubMedSuche in Google Scholar
  • 41 Colombel JF, Sandborn WJ, Rutgeerts P , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132 (1) 52-65
    CrossrefPubMedSuche in Google Scholar
  • 42 Sandborn WJ, Abreu MT, D'Haens G , et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8 (8) 688-695 , e2
    CrossrefPubMedSuche in Google Scholar
  • 43 Lichtenstein GR, Rutgeerts P, Sandborn WJ , et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107 (7) 1051-1063
    CrossrefPubMedSuche in Google Scholar
  • 44 Colombel JF, Sandborn WJ, Reinisch W , et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362 (15) 1383-1395
    CrossrefPubMedSuche in Google Scholar
  • 45 Thia KT, Mahadevan U, Feagan BG , et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15 (1) 17-24
    CrossrefPubMedSuche in Google Scholar
  • 46 Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302 (18) 981-987
    CrossrefPubMedSuche in Google Scholar
  • 47 Present DH, Rutgeerts P, Targan S , et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340 (18) 1398-1405
    CrossrefPubMedSuche in Google Scholar
  • 48 Sands BE, Anderson FH, Bernstein CN , et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350 (9) 876-885
    CrossrefPubMedSuche in Google Scholar
  • 49 Sands BE, Blank MA, Patel K, van Deventer SJ. ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2 (10) 912-920
    CrossrefPubMedSuche in Google Scholar
  • 50 Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011; 33 (2) 185-193
    CrossrefPubMedSuche in Google Scholar
  • 51 Ochsenkühn T, Göke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97 (8) 2022-2025
    CrossrefPubMedSuche in Google Scholar
  • 52 Schröder O, Blumenstein I, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 2004; 19 (3) 295-301
    CrossrefPubMedSuche in Google Scholar
  • 53 Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9 (2) 98-103
    CrossrefPubMedSuche in Google Scholar
  • 54 Sciaudone G, Di Stazio C, Limongelli P , et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg 2010; 53 (5) 299-304
    PubMedSuche in Google Scholar
  • 55 Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011; 141 (1) 90-97
    CrossrefPubMedSuche in Google Scholar
  • 56 Rutgeerts P, Hiele M, Geboes K , et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108 (6) 1617-1621
    CrossrefPubMedSuche in Google Scholar
  • 57 Rutgeerts P, Van Assche G, Vermeire S , et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128 (4) 856-861
    CrossrefPubMedSuche in Google Scholar
  • 58 Hanauer SB, Korelitz BI, Rutgeerts P , et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127 (3) 723-729
    CrossrefPubMedSuche in Google Scholar
  • 59 D'Haens GR, Vermeire S, Van Assche G , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135 (4) 1123-1129
    CrossrefPubMedSuche in Google Scholar
  • 60 Regueiro M, Schraut W, Baidoo L , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136 (2) 441-450 , e1, quiz 716
    CrossrefPubMedSuche in Google Scholar